Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction

Brodeur, 2003, Neuroblastoma: biological insights into a clinical enigma, Nat. Rev. Cancer, 3, 203, 10.1038/nrc1014 Maris, 2007, Neuroblastoma, Lancet, 369, 2106, 10.1016/S0140-6736(07)60983-0 Park, 2008, Neuroblastoma: biology, prognosis, and treatment, Pediatr. Clin. North. Am., 55, 97, 10.1016/j.pcl.2007.10.014 Vandesompele, 2005, Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma, J. Clin. Oncol., 23, 2280, 10.1200/JCO.2005.06.104 Schwab, 2003, Neuroblastoma: biology and molecular and chromosomal pathology, Lancet Oncol., 4, 472, 10.1016/S1470-2045(03)01166-5 Berwanger, 2002, Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma, Cancer Cell, 2, 377, 10.1016/S1535-6108(02)00179-4 Oberthuer, 2006, Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification, J. Clin. Oncol., 24, 5070, 10.1200/JCO.2006.06.1879 Ohira, 2005, Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas, Cancer Cell, 7, 337, 10.1016/j.ccr.2005.03.019 Schramm, 2007, Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome, Clin. Cancer Res., 13, 1459, 10.1158/1078-0432.CCR-06-2032 Schulte, 2008, MYCN regulates oncogenic MicroRNAs in neuroblastoma, Int. J. Cancer, 122, 699, 10.1002/ijc.23153 Chen, 2008, An integrated cross-platform prognosis study on neuroblastoma patients, Genomics, 10.1016/j.ygeno.2008.05.014 Kaderali, 2006, CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data, Bioinformatics, 22, 1495, 10.1093/bioinformatics/btl103 Schulte, 2005, Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas, Oncogene, 24, 165, 10.1038/sj.onc.1208000 Schramm, 2005, Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling, Oncogene, 24, 7902, 10.1038/sj.onc.1208936 Mierswa, 2006, RapidMiner/YALE: Rapid Prototyping for Complex Data Mining Tasks, 935 Cohn, 1995, Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study, Cancer Res., 55, 721 Tonini, 1997, MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children, J. Clin. Oncol., 15, 85, 10.1200/JCO.1997.15.1.85 Vapnik, 1995 Hastie, 2001 Varma, 2006, Bias in error estimation when using cross-validation for model selection, BMC Bioinformatics, 7, 91, 10.1186/1471-2105-7-91 Asgharzadeh, 2006, Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification, J. Natl. Cancer Inst., 98, 1193, 10.1093/jnci/djj330 Shmueli, 2001, DCX in PC12 cells: CREB-mediated transcription and neurite outgrowth, Hum. Mol. Genet., 10, 1061, 10.1093/hmg/10.10.1061 Oltra, 2005, The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma, Diagn. Mol. Pathol., 14, 53, 10.1097/01.pas.0000149876.32376.c0 Viprey, 2008, Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials, J. Pathol., 216, 245, 10.1002/path.2406 Schilling, 2002, Neuroblastoma screening at one year of age, New Engl. J. Med., 346, 1047, 10.1056/NEJMoa012277 Ohira, 2003, Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets, Oncogene, 22, 5525, 10.1038/sj.onc.1206853 Oberthuer, 2008, Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR, Clin. Cancer Res., 14, 6590, 10.1158/1078-0432.CCR-07-4377